Statement Of Cash Flows [Abstract]

Tchaikapharma High Quality Medicines AD - Filing #6023728

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
- BGN
- BGN
3 398 BGN
- BGN
- BGN
3 398 BGN
3 398 BGN
- BGN
- BGN
2 790 BGN
- BGN
2 790 BGN
2 790 BGN
- BGN
Income taxes paid (refund), classified as operating activities
393,000 BGN
445,000 BGN
Other inflows (outflows) of cash, classified as operating activities
5 522 BGN
5 036 BGN
Cash flows from (used in) operating activities
2 864 BGN
2 461 BGN
Cash flows from (used in) investing activities [abstract]
Purchase of other long-term assets, classified as investing activities
1 912 BGN
1 580 BGN
Cash flows from (used in) investing activities
1 912 BGN
1 580 BGN
Cash flows from (used in) financing activities [abstract]
Proceeds from borrowings, classified as financing activities
527,000 BGN
247,000 BGN
Repayments of borrowings, classified as financing activities
527,000 BGN
248,000 BGN
Payments of lease liabilities, classified as financing activities
522,000 BGN
522,000 BGN
Dividends paid, classified as financing activities
499,000 BGN
273,000 BGN
Cash flows from (used in) financing activities
1 021 BGN
796,000 BGN
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
69,000 BGN
85,000 BGN
Cash and cash equivalents
73,000 BGN
142,000 BGN
57,000 BGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.